IP Rights · Patents
Patents
Bacosane®'s intellectual property portfolio covers its standardized Bacopa monnieri extract technology across the United States, India and the PCT route.
Portfolio
Granted patent and applications
| Patent / Application No. | Territory | Status | Filing information |
|---|---|---|---|
| US 12,357,924 B2 | United States | Granted patent | US Application No. 17/570,918 — filed 7 Jan 2022 |
| 202141036735 | India | Patent application published | Filed 13 Aug 2021 — published 17 Feb 2023 |
| PCT/IB2021/059307 | International (PCT) | International application | Filed 12 Oct 2021 |
Scope
What the portfolio relates to
- • Standardization of Bacopa monnieri extract containing eight standardized bioactives
- • Inclusion of asiatic acid, ebelin lactone, bacogenin A1, bhramic acid, bacoside A3, bacopaside I, bacopaside II and jujubogenin within the composition
- • Neuroprotective support for hippocampal and synaptic functions
- • Applications for memory, learning, concentration and stress management
- • Pharmacological properties across antioxidant, anxiolytic and anticonvulsant models
Notice
Patent usage notice
Patent rights and scope may differ between territories and may change during examination, opposition, maintenance or expiry. Manufacturers, distributors and brands are encouraged to verify current legal status and freedom-to-operate for their intended product, formulation, claim and market.